ABX-CRO

Anavex successfully completes phase I Alzheimer’s trial

Monday, November 14, 2011

Anavex Life Sciences has successfully completed its phase I single ascending dose (SAD) clinical trial of ANAVEX 2-73, the company’s lead drug candidate for the treatment of Alzheimer’s Disease.  ANAVEX 2-73 is the first of a new class of oral drugs being studied to potentially treat AD through disease modification rather than focusing only on symptomatic improvement.

[Read More]